{"id":800662,"date":"2025-01-14T11:22:58","date_gmt":"2025-01-14T16:22:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/"},"modified":"2025-01-14T11:22:58","modified_gmt":"2025-01-14T16:22:58","slug":"hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/","title":{"rendered":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Jan.  14, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2r_egpmaf_uv-39P4eB185hR9ghotevOaRnwrqBLQH3zON1V8sUKDtOv9Bf-5wHop_iYCU8Kr1Qb9QEEXo5gGHLikLetRYvG1ZFCJKel-YC5QujD5WcXbCAIzxn3ryer\" rel=\"nofollow\" target=\"_blank\"><u>Monteverde &amp; Associates PC<\/u><\/a> (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a <strong>Top 50\u00a0Firm <\/strong>by ISS Securities Class Action Services Report. We are headquartered at the<strong>\u00a0Empire State Building<\/strong>\u00a0in New York City and are investigating <strong>Salarius Pharmaceuticals, Inc. <\/strong><strong>(<\/strong><strong>Nasdaq<\/strong><strong>: <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YUwVtdcO6vHJIYd08FSbnOTDM_9Nz5g-v3Qb8nTNcCBOqbDXHYTgPuClcSN8GX6FhPcNn7DWPtw9uytFh5uLAa-JWzPg_KbehFHnRs8qMjw=\" rel=\"nofollow\" target=\"_blank\"><strong>SLRX<\/strong><\/a><strong>)<\/strong>, relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company.<\/p>\n<p>\n        <strong>Click here for more <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IExqkp6s9A-myk_E34_v35ydDhh97Mn8b5Q9-D-coxueiP8zOyMxCJm2MjwSAD2q_KXo9xXc9nxaAi4xA8uCmmuFV4pyzDdmwS46KFNh5y16Oh3V3E7WfeqsBdu7qBF8_5W8W5_Z7671T4PfBRR0SReiYrX91E12yLp5RWWi3C6-z_Mqe1ACRrUYdr3dLeNVn_TraarfaciqgAneTST5dg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/monteverdelaw.com\/case\/salarius-pharmaceuticals-inc-slrx\/<\/a>. <strong>It is free and there is no cost or obligation to you.<\/strong><\/p>\n<p>\n        <strong>NOT ALL LAW FIRMS ARE THE SAME. <\/strong>Before you hire a law firm, you should talk to a lawyer and ask:<\/p>\n<ol style=\"list-style-type:decimal\">\n<li>Do you file class actions and go to Court?<\/li>\n<li>When was the last time you recovered money for shareholders?<\/li>\n<li>What cases did you recover money in and how much?<\/li>\n<\/ol>\n<p>\n        <strong>About Monteverde &amp; Associates PC<\/strong>\n      <\/p>\n<p align=\"justify\">Our firm litigates and has recovered money for shareholders\u2026and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S.\u00a0Supreme Court.\u00a0<\/p>\n<p>\n        <strong>No company, director or officer is above the law.<\/strong> If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B58izB-zZQSKpQLT4qUwIisK74AHyEskoPYtQeuqRTjNtn4wND4XlAg9x1f5T6lMQ1VIo946lEXJdQScNa-sLbNGDOJKOU_ELIZ5DqO2Gg0I_QhnlSUJi7yZHA_p4IIHjoN0nT0-xPqGAMWwUQGS2z0lYvqUgfyC78esyHq9jHsRUTx0fSc7Ja2srcaLEp9F\" rel=\"nofollow\" target=\"_blank\"><strong><u>website<\/u><\/strong><\/a> or contact Juan Monteverde, Esq. either via e-mail at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FfptTrCZfDyhv7ISXwH0t19z8twJrNssiXL7cTvd9rvxFE0PSsfnr4i_du1XmBQu1zC_JiWzFcYDVpAOxlUxBTTP4dfbmrGBfIWz-bxzNtDZ69vQcuG6yaEyatYveYDW\" rel=\"nofollow\" target=\"_blank\"><strong><u>jmonteverde@monteverdelaw.com<\/u><\/strong><\/a> or by telephone at (212) 971-1341.<\/p>\n<p>Contact:<br \/>Juan Monteverde, Esq.<br \/>MONTEVERDE &amp; ASSOCIATES PC<br \/><strong>The Empire State Building<\/strong><br \/>350 Fifth Ave. Suite 4740<br \/>New York, NY 10118<br \/>United States of America<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FfptTrCZfDyhv7ISXwH0t19z8twJrNssiXL7cTvd9rs1ZjzrhK9vkBMBKfdNipGl7B7eP_qNZUmOsLHtD1FvgoBXZjyJIgcJos9wqv03UwRjXpVannRepCtpZ3ENRaq-\" rel=\"nofollow\" target=\"_blank\"><u>jmonteverde@monteverdelaw.com<\/u><\/a><br \/>Tel: (212) 971-1341<\/p>\n<p>Attorney Advertising. (C) 2024 Monteverde &amp; Associates PC.\u00a0The law firm responsible for this advertisement is Monteverde &amp; Associates PC (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nDJq14mEVlw1M-h0rFdmWyQMYE5rxLR0_phPVYFdGIvJakZ5YgtjZ29DweSfrFM9sF-2DIgrb3tTfCH6KBFMmhzYtq-mwS0kwOL24bAkbEkjHBoLj7rrjwwsIVWApazWK8fCxuD8Fjwk9XNATtLe6mniRdNVQ0BE8zEUkAjMh-2XhvBUhYHbi9vUNpsPVVWAokoDUF0hUd5G43Bhtzjdtij5FszUu8lWQEh049dET64=\" rel=\"nofollow\" target=\"_blank\"><u>www.monteverdelaw.com<\/u><\/a>).\u00a0 Prior results do not guarantee a similar outcome with respect to any future matter.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDBkNGM5NDUtNmZkNi00OGYwLTk3ZjItN2Y0ZGQwYzM4ZDczLTExOTU5MTM=\/tiny\/Monteverde-Associates-PC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) &#8212; Monteverde &amp; Associates PC (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a Top 50\u00a0Firm by ISS Securities Class Action Services Report. We are headquartered at the\u00a0Empire State Building\u00a0in New York City and are investigating Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company. Click here for more https:\/\/monteverdelaw.com\/case\/salarius-pharmaceuticals-inc-slrx\/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-800662","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) &#8212; Monteverde &amp; Associates PC (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a Top 50\u00a0Firm by ISS Securities Class Action Services Report. We are headquartered at the\u00a0Empire State Building\u00a0in New York City and are investigating Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company. Click here for more https:\/\/monteverdelaw.com\/case\/salarius-pharmaceuticals-inc-slrx\/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a &hellip; Continue reading &quot;$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T16:22:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX\",\"datePublished\":\"2025-01-14T16:22:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/\"},\"wordCount\":339,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/\",\"name\":\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=\",\"datePublished\":\"2025-01-14T16:22:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/","og_locale":"en_US","og_type":"article","og_title":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX - Market Newsdesk","og_description":"NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) &#8212; Monteverde &amp; Associates PC (the \u201cM&amp;A Class Action Firm\u201d), has recovered millions of dollars for shareholders and is recognized as a Top 50\u00a0Firm by ISS Securities Class Action Services Report. We are headquartered at the\u00a0Empire State Building\u00a0in New York City and are investigating Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company. Click here for more https:\/\/monteverdelaw.com\/case\/salarius-pharmaceuticals-inc-slrx\/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a &hellip; Continue reading \"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-14T16:22:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX","datePublished":"2025-01-14T16:22:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/"},"wordCount":339,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/","name":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=","datePublished":"2025-01-14T16:22:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTgzMSM2NjkzNjkyIzIxODQzNTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-salarius-pharmaceuticals-inc-slrx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"$HAREHOLDER ALERT: The M&amp;A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. \u2013 SLRX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=800662"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800662\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=800662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=800662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=800662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}